skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

91 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Interview: Why Europe's Biotech Prime Time Is Now

By sten-stovall 23 Oct 2019

VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.

Topic business-strategies drug-review

Biomedtracker: 開発中医薬品をFDA承認確率で評価

Q3 2019 Catalyst Roundup

16 Oct 2019

What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

Topic Drug approval Drug review FDA

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Pink Sheet Performance Trackers: Navigate a complex world with the regulatory performance trackers from Pink Sheet

16 Oct 2019

 Pink Sheet Performance Trackers: Navigate a complex world with the regulatory performance trackers from Pink Sheet

Keep track of compliance, legislation, policy regulations, and industry developments with the expertise of our worldwide network of expert analysts and journalists on the ground in key global regions.

Topic drug-development-landscape drug-review fda

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...

Key potential drug launches 2020

27 Sep 2019

Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

Topic drug-approval drug-review drug-development-landscape

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Inclisiran’s Safety Data Suggest Game-Changing Potential In PCSK9 Market

11 Sep 2019

Inclisiran’s Safety Data Suggest Game-Changing Potential In PCSK9 Market

The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent. 

Topic drug-development-landscape drug-review

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

03 Sep 2019

As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations

Topic drug-review

Pharmaprojects: 医薬品開発パイプラインのデータベース


By Jonathan Slater 02 Sep 2019

米国で抗生物質開発インセンティブ法(Generating Antibiotic Incentives Now)が施行されてから7年になります。この法律は薬剤耐性菌が世界的に増加している状況に対して、新規抗菌薬の開発を支援することを目的としています。7年を経た今、状況はどうようになったでしょうか。製薬業界全体と臨床試験の動向をホワイトペーパー『QIDP: What have we gained』にまとめました。

Topic drug-development-landscape drug-review

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Oncology Market Leaders Maintain Their Upper Hand

14 Aug 2019

Oncology Market Leaders Maintain Their Upper Hand

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts. 

Topic Drug development landscape Drug review





電話:+81 (0)3 6273 4260